SAN DIEGO – April 2, 2019 – NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the Company will showcase industry-leading solutions designed to deliver better clinical outcomes for spinal procedures at the British Association of Spinal Surgeons (BASS) conference and exhibition being held April 3-5, 2019 at the Brighton Centre in Brighton, United Kingdom.
During BASS 2019, NuVasive will showcase its Pulse™ surgical automation platform with the integration of the Siemens Healthineers’ Cios Spin cutting-edge mobile 3D C-arm. Upon commercial availability later this year, the Pulse platform will incorporate neuromonitoring, surgical planning, rod bending, smart imaging and navigation.
NuVasive will also feature its Advanced Materials Science™ (AMS) portfolio, including its proprietary Modulus® Titanium XLIF and Cohere® Porous PEEK™ interbody implants. Greg Williams, PhD, director of Biologics R&D at NuVasive, will speak on AMS at the podium presentation “Creating the New Architectures of Spinal Interbody Cages” on Wednesday, April 3, 2019 at 17:00 BST in auditorium two. Dr. Williams will present on rapidly evolving implant designs and manufacturing methods, including innovative porous architectures. Discussion of the types of nano-, micro- and macroscale features that drive the strongest integration with bone will draw on recent clinical and preclinical research.
“NuVasive continues to lead the spine industry with technologies that enable surgeons to provide better clinical outcomes for patients and more cost-effective solutions for hospitals, improving the overall quality of care,” said Erin McEachren, commercial vice president of Europe at NuVasive. “Surgeons will see firsthand the impact NuVasive’s enabling technologies have in helping deliver more predictable spine surgery.”
Conference attendees can visit NuVasive at stand 38 to experience the latest innovative spine solutions and systems firsthand from NuVasive’s team of experts.
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company’s portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With more than $1 billion in revenues, NuVasive has approximately 2,600 employees and operates in more than 50 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA® platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
Investor & Media Contact: